3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Classical hematology
4
Conditions
Breast Neoplasms
298
Carcinoma, Non-Small-Cell Lung
226
Neoplasms
155
Prostatic Neoplasms
154
Multiple Myeloma
116
Neoplasm Metastasis
83
Colorectal Neoplasms
80
Leukemia, Myeloid, Acute
74
Lung Neoplasms
71
Parkinson Disease 4, Autosomal Dominant Lewy Body
68
Melanoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Follicular
62
Lymphoma, Non-Hodgkin
61
Papillomavirus Infections
59
Leukemia
59
Pain
52
Lymphoma
52
Uterine Cervical Neoplasms
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
49
Ovarian Neoplasms
47
Carcinoma, Hepatocellular
46
Keratosis, Actinic
44
Carcinoma, Renal Cell
44
Recurrence
43
Head and Neck Neoplasms
43
Stomach Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
34
Urinary Bladder Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
32
Interventions
emicizumab
4
recombinant FVIIa
1
anti-inhibitor coagulant complex
1
Factor VIII
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Has results
×
Hemophilia A
×
Clear all
NCT03020160
2023-01-11
HAVEN 4
Hoffmann-La Roche
Phase 3
Completed
48 enrolled
44 charts
1 FDA
NCT02847637
2022-11-16
HAVEN 3
Hoffmann-La Roche
Phase 3
Completed
152 enrolled
46 charts
1 FDA
NCT02622321
2021-06-24
HAVEN 1
Hoffmann-La Roche
Phase 3
Completed
113 enrolled
45 charts
1 FDA
NCT02795767
2021-06-02
HAVEN 2
Hoffmann-La Roche
Phase 3
Completed
88 enrolled
65 charts
1 FDA